31 October 2016 - South Korean biopharma developer Celltrion said Monday that it has submitted its Herceptin biosimilar to the European Medicine Agency for approval, taking a step closer to commercialising the drug in European markets.

Celltrion submitted Herzuma to the EMA on 27 October. Herzuma is a biosimilar referencing Roche’s blockbuster breast cancer drug Herceptin (trastuzumab) which raked in a revenue of $6.8 billion worldwide in 2015.

Read Korean Herald article